Trial Profile
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Jul 2022 This trial has been completed in Germany, according to European Clinical Trials Database record. (end date:2013-02-25)
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (2013-02-25)
- 09 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.